title: Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
abstract: Therapeutic immune checkpoint blockade for metastatic melanoma has been associated with vitiligo, pruritus and morbilliform eruptions. Reports of other autoimmune skin disease in this setting are rare. We sought to expand the spectrum of cutaneous immune-mediated effects related to immune checkpoint inhibitor therapy. In this report, we describe two unusual cutaneous reactions related to checkpoint inhibitor therapy, namely bullous pemphigoid (BP) and dermatitis herpetiformis. The development of BP and dermatitis herpetiformis in the context of checkpoint inhibitor therapy is consistent with previous investigations supporting the importance of effector and regulatory T cells in the pathogenesis of these diseases.
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Mark C
authors.initials: MC
authors.lastname: Mochel
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Ming
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Sotonye
authors.initials: S
authors.lastname: Imadojemu
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Tara C
authors.initials: TC
authors.lastname: Gangadhar
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Lynn M
authors.initials: LM
authors.lastname: Schuchter
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Rosalie
authors.initials: R
authors.lastname: Elenitsas
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Aimee S
authors.initials: AS
authors.lastname: Payne
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: Emily Y
authors.initials: EY
authors.lastname: Chu
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000473:pathology; D003874:Dermatitis Herpetiformis / Q000139:chemically induced* / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology*; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000139:chemically induced* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074324:Ipilimumab; C582435:pembrolizumab
keywords: bullous pemphigoid; dermatitis herpetiformis; drug reaction; immunotherapy; melanoma